Chang Carmen's Form 4 filing
SpyGlass Pharma, Inc. (SGP) · filed Feb 11, 2026
- Accession no.
- 0001193125-26-046663
- Filed
- Feb 11, 2026
- Trade date
- Feb 9, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 7 non-derivative transactions and 6 derivative transactions. Open-market purchases total $15.0M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Chang CarmenCIK 0001746342 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | Common Stock | CConversionAcquired | +1,619,240 | –F1 | – | 1,619,240 | Indirect | Duplicate filing |
| Feb 9, 2026 | Common Stock | CConversionAcquired | +1,370,168 | –F1 | – | 2,989,408 | Indirect | Duplicate filing |
| Feb 9, 2026 | Common Stock | CConversionAcquired | +1,370,168 | –F1 | – | 4,359,576 | Indirect | Duplicate filing |
| Feb 9, 2026 | Common Stock | CConversionAcquired | +737,962 | –F1 | – | 5,097,538 | Indirect | Duplicate filing |
| Feb 9, 2026 | Common Stock | PPurchaseAcquired | +937,500 | $16.00 | +$15,000,000 | 6,035,038 | Indirect | Duplicate filing |
| Feb 9, 2026 | Common Stock | CConversionAcquired | +954,990 | –F1 | – | 954,990 | Indirect | Duplicate filing |
| Feb 9, 2026 | Common Stock | CConversionAcquired | +402,273 | –F1 | – | 1,357,263 | Indirect | Duplicate filing |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | Common Stock | CConversionDisposed | −1,619,240 | –F1 | – | 0 | Indirect | Duplicate filing |
| Feb 9, 2026 | Common Stock | CConversionDisposed | −1,370,168 | –F1 | – | 0 | Indirect | Duplicate filing |
| Feb 9, 2026 | Common Stock | CConversionDisposed | −1,370,168 | –F1 | – | 0 | Indirect | Duplicate filing |
| Feb 9, 2026 | Common Stock | CConversionDisposed | −737,962 | –F1 | – | 0 | Indirect | Duplicate filing |
| Feb 9, 2026 | Common Stock | CConversionDisposed | −954,990 | –F1 | – | 0 | Indirect | Duplicate filing |
| Feb 9, 2026 | Common Stock | CConversionDisposed | −402,273 | –F1 | – | 0 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026.
Referenced by the price of 6 transactions in Table I and 6 transactions in Table II.